

Vascular Liver Disorders, Portal Vein Thrombosis, and Portal Hypertension  
With Liver Disease: 2020 Practice Guidance by the American Association of  
Liver Diseases

Hepatology

73, 366-413

DOI: [10.1002/hep.31646](https://doi.org/10.1002/hep.31646)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Recommendations for management of portal vein thrombosis in cirrhosis. <i>Journal of Digestive Diseases</i> , 2021, 22, 174-175.	0.7	2
2	Surgical Perspectives on the American Association for the Study of Liver Diseases Guideline for Anticoagulation and Implications for Liver Transplantation. <i>Liver Transplantation</i> , 2021, 27, 580-583.	1.3	1
3	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1116-1122.	1.9	66
4	Step by Step: Managing the Complications of Cirrhosis. <i>Hepatic Medicine: Evidence and Research</i> , 2021, Volume 13, 45-57.	0.9	11
5	Treatment of bleeding in patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1644-1652.	1.9	16
6	Portal vein thrombosis: an overview of current treatment options. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 327-332.	0.4	13
7	Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 535-552.	4.5	7
8	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1636-1662.e36.	2.4	95
10	Tranexamic Acid Is Not a Universal Hemostatic Agent. <i>HemaSphere</i> , 2021, 5, e625.	1.2	3
11	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	1.9	29
12	TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy. <i>Hepatology</i> , 2021, 74, 2735-2744.	3.6	32
13	Fresh frozen plasma in treating acute variceal bleeding: Not effective and likely harmful. <i>Liver International</i> , 2021, 41, 1710-1712.	1.9	2
14	A unique case of bleeding from esophageal varices as the first sign of essential thrombocythemia. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1612-1616.	0.4	0
15	Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2022, 54, 56-62.	0.4	26
16	Therapeutic anticoagulation after liver transplantation is not useful among patients with pre-transplant Yerdelâ€grade I/II portal vein thrombosis: A two-center retrospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2760-2771.	1.9	2
17	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	2.0	16
18	Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded?. <i>Digestive and Liver Disease</i> , 2021, 53, 1394-1395.	0.4	3
19	A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. <i>Hepatology International</i> , 2021, 15, 1196-1206.	1.9	16

#	ARTICLE	IF	CITATIONS
20	Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2021, 53, 1396-1403.	0.4	7
21	Minor Role of Hemostatic Alternation in Portal Vein Thrombosis Pathogenesis Revealed by Global Measurement. <i>Journal of Hepatology</i> , 2021, , .	1.8	1
23	Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. <i>Journal of Digestive Diseases</i> , 2021, 22, 506-519.	0.7	2
24	AGA Technical Review on Coagulation in Cirrhosis. <i>Gastroenterology</i> , 2021, 161, 1630-1656.	0.6	14
25	The clinical impact of chronic liver disease in patients undergoing transcatheter and surgical aortic valve replacement: Systematic analysis of the 2011â€“2017 <scp>US</scp> hospital database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E1044-E1057.	0.7	6
26	A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation. <i>JHEP Reports</i> , 2021, 3, 100363.	2.6	11
27	Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 18025.	1.6	20
28	Recanalization of Chronic Noncirrhotic, Nonmalignant Splanchnic Thromboses is Feasible: A Transsplenic Assisted Patient-Tailored Approach. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1377-1385.	0.2	6
29	AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. <i>Gastroenterology</i> , 2021, 161, 1615-1627.e1.	0.6	43
30	Management of Thrombocytopenia and Coagulopathy in Patients with Chronic Liver Disease Undergoing Therapeutic Endoscopic Interventions. <i>Clinics in Liver Disease</i> , 2021, 26, 1-12.	1.0	2
31	Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start?. <i>Digestive and Liver Disease</i> , 2021, 53, 1364-1365.	0.4	0
32	When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?. <i>Current Opinion in Pharmacology</i> , 2021, 60, 111-116.	1.7	2
33	Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00409.	1.3	8
34	Challenging anticoagulation cases: Acute extensive portal vein thrombosis in a patient without cirrhosis â€“ Evidence-based management of a rare clinical entity. <i>Thrombosis Research</i> , 2021, 206, 133-136.	0.8	0
35	Second-generation thrombopoietin receptor agonists: New players in the management of cirrhotic patients undergoing therapeutic endoscopy?. <i>Digestive and Liver Disease</i> , 2021, 53, 1362-1363.	0.4	1
36	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1278-1285.e2.	0.6	15
37	Metaâ€“analysis and systematic review: Prevalence, graft failure, mortality, and postâ€“operative thrombosis in liver transplant recipients with preâ€“operative portal vein thrombosis. <i>Clinical Transplantation</i> , 2022, 36, e14520.	0.8	11
38	Editorial commentary on <i>Indian Journal of Gastroenterology</i> â€“Septemberâ€“October 2021. <i>Indian Journal of Gastroenterology</i> , 2021, , 1.	0.7	0

#	ARTICLE	IF	CITATIONS
39	Rivaroxaban-calibrated chromogenic anti-Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12594.	1.0	0
40	Portal Vein Thrombosis In Cirrhosis: Interventional Treatment Options. <i>Current Gastroenterology Reports</i> , 2021, 23, 24.	1.1	4
41	Portal Vein Thrombosis: Diagnosis and Endovascular Management. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, 194, 169-180.	0.7	11
42	Primary Budd-Chiari Syndrome With Right Atrial Extension: A Rare Presentation of Intrahepatic Cholangiocarcinoma. <i>Cureus</i> , 2021, 13, e18935.	0.2	0
43	State of the Art in Hepatic Dysfunction in Pregnancy. <i>Healthcare (Switzerland)</i> , 2021, 9, 1481.	1.0	3
44	Direct oral anticoagulants for portal vein thrombosis in cirrhosis: Good news from meta-analysis?. <i>Digestive and Liver Disease</i> , 2022, 54, 54-55.	0.4	2
45	Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. <i>Hepatology Communications</i> , 2022, 6, 423-434.	2.0	5
46	Reply. <i>Hepatology</i> , 2022, 75, 499-499.	3.6	0
47	New Portal Vein Thrombosis in Cirrhosis - is the Thrombophilia Exacerbated due to Vaccine or COVID-19?. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1025-1028.	0.4	7
48	Portal Vein Thrombosis in Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 965-979.	0.4	17
49	Ultrasonography in the diagnosis of complications in patients with portal hypertension. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 347-358.	0.6	1
50	Assessing the Complicated Venous Hemodynamics and Therapeutic Outcomes of Budd-Chiari Syndrome with Respiratory-gated 4D Flow MR Imaging During the Expiratory and Inspiratory Phases. <i>Magnetic Resonance in Medical Sciences</i> , 2023, 22, 1-6.	1.1	2
51	Treatment of portal vein thrombosis: an updated narrative review. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
52	Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice. <i>Phlebology</i> , 2022, , 026835552110689.	0.6	4
53	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. <i>American Journal of Hematology</i> , 2022, 97, 431-439.	2.0	7
55	Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation. <i>Transplantation</i> , 2022, 106, 1123-1131.	0.5	17
56	Perioperative management of patients with liver disease. <i>BJA Education</i> , 2022, 22, 111-117.	0.6	2
57	Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24240.	0.9	2

#	ARTICLE	IF	CITATIONS
58	Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. <i>Abdominal Radiology</i> , 2022, 47, 1177-1186.	1.0	4
59	Safety of Transesophageal Echocardiogram in Patients with Cirrhosis and Esophageal Varices. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 444-445.	1.2	1
60	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	1.8	26
61	Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 596-606.	1.5	7
62	Update on the management of gastric varices. <i>Liver International</i> , 2022, 42, 1250-1258.	1.9	12
63	Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5290-5299.	1.1	17
64	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	1.9	17
65	Nontransplant options for portomesenteric thrombosis. <i>Current Opinion in Organ Transplantation</i> , 2022, Publish Ahead of Print, .	0.8	0
66	Baveno VII "Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	1.8	890
67	Clinical Predictors for Thrombus Progression in Cirrhotic Patients with Untreated Splanchnic Vein Thrombosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
68	Treatment of Atypical Clots. <i>Hamostaseologie</i> , 2022, 42, 010-018.	0.9	0
69	Re: Clinical utility of transient elastography in the management of patients with Budd-Chiari syndrome undergoing endovascular intervention. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.2	0
70	Case Report: Pancreatic Neuroendocrine Tumor With Liver Metastasis and Portal Vein Thrombosis. <i>Frontiers in Oncology</i> , 2021, 11, 809129.	1.3	2
71	Antithrombotic Therapy After Venous Interventions: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 219, 175-187.	1.0	8
72	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 1151-1184.	1.8	112
73	Transjugular intrahepatic portosystemic shunt in patients with autoimmune hepatitis-induced cirrhosis and variceal bleeding. <i>Abdominal Radiology</i> , 2022, 47, 1464-1472.	1.0	1
74	Avatrombopag, a new tool for the management of thrombocytopenia in patients undergoing medical procedures. <i>Schweizer Gastroenterologie</i> , 2022, 3, 37-40.	0.0	0
75	Coagulopathy and hemostasis management in patients undergoing liver transplantation: Defining a dynamic spectrum across phases of care. <i>Liver Transplantation</i> , 2022, 28, 1651-1663.	1.3	9

#	ARTICLE	IF	CITATIONS
76	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	1.8	43
77	Large-bore mechanical thrombectomy for subacute portal vein thrombosis in patient with acute bleeding. , 2022, , .		0
78	Rebalanced hemostasis in liver disease: a misunderstood coagulopathy. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 485-491.	0.9	6
79	Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies. <i>Frontiers in Medicine</i> , 2021, 8, 794599.	1.2	15
80	Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. <i>Liver International</i> , 2022, 42, 435-443.	1.9	8
81	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. <i>Blood Advances</i> , 2022, 6, 3569-3578.	2.5	19
82	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	2.6	17
83	Pathophysiology and management of bleeding and thrombosis in patients with liver disease. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 79-88.	0.7	4
84	Portal vein thrombosis is associated with an increased risk of bone fractures. <i>PLoS ONE</i> , 2022, 17, e0267535.	1.1	1
85	Association of endoscopic variceal treatment with portal venous system thrombosis in liver cirrhosis: a case-control study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210875.	1.4	3
86	Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2022, 54, 1520-1526.	0.4	12
87	Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?. <i>World Journal of Hepatology</i> , 2022, 14, 682-695.	0.8	5
88	Anticoagulation in Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 536-545.	1.1	4
89	Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances. <i>World Chinese Journal of Digestology</i> , 2022, 30, 381-386.	0.0	0
90	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	2.4	12
91	Acute hepatitis with portal and mesenteric vein thrombosis revealing SARS-CoV-2 infection: Case report and literature review. <i>Annals of Medicine and Surgery</i> , 2022, 77, 103706.	0.5	1
92	Three-fold Increased Risk of Death in Budd-Chiari Syndrome Compared to Matched Controls: A Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 995-1004.e9.	2.4	1
93	Haemostatic alterations and management of haemostasis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 1291-1305.	1.8	33

#	ARTICLE	IF	CITATIONS
94	Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China. <i>Liver International</i> , 2023, 43, 18-33.	1.9	7
95	Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12724.	1.0	3
96	Author's reply: "Staging the pre-procedural prophylaxis in decompensated cirrhosis". <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0
97	Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2022, 216, 1-7.	0.8	6
98	The Course of Alcoholic Cirrhosis of The Liver in a Patient with COVID-19. <i>Russian Archives of Internal Medicine</i> , 2022, 12, 234-239.	0.0	0
99	Incidence and outcomes of thromboembolic and bleeding events in patients with liver cirrhosis in the <scp>USA</scp>. <i>Liver International</i> , 2023, 43, 434-441.	1.9	2
100	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.4	5
101	Review article: thromboelastography in liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 580-591.	1.9	3
102	Small Bowel Perforation Secondary to Portal Vein Thrombosis. <i>Cureus</i> , 2022, , .	0.2	0
103	Timing of Treatment for Budd-Chiari syndrome: still an open issue. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, , .	0.4	0
104	Portal Vein Thrombosis Risk Factors in Liver Transplant Candidates. <i>Hepatology Forum</i> , 2022, , .	0.3	4
105	The international normalized ratio "Great for prediction of bleeding in patients taking vitamin K antagonists, useless for prediction of bleeding in patients with chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1565-1567.	1.9	0
106	Comparison of transjugular intrahepatic portosystemic with endoscopic treatment plus anticoagulation for esophageal variceal bleeding and portal vein thrombosis in liver cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1494-1502.	0.6	3
107	Effect of underdiluted transjugular intrahepatic portosystemic shunt on prognosis in patients with prior splenectomy: a propensity score-matched case-control study. <i>Abdominal Radiology</i> , 2022, 47, 3615-3627.	1.0	5
108	Characterization of Biomarkers of Hemostasis and Bleeding-Related Outcomes in Children With Cirrhosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 75, 506-513.	0.9	1
109	Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. <i>Advances in Therapy</i> , 2022, 39, 4169-4188.	1.3	3
110	Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding in patients with chronic liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 1421-1437.	0.8	1
111	Vascular liver diseases: A sex-oriented analysis of the literature. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0

#	ARTICLE	IF	CITATIONS
112	Plasma, platelets and cryoprecipitates therapies. <i>AboutOpen</i> , 0, 9, 52-57.	0.2	0
113	Chronic Portal Vein Thrombosis with Percutaneous Main Portal Vein Reconstruction and Coil Embolization of a Massive Coronary Vein: A Case Report. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	0
114	Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review. <i>Journal of Emergency Medicine</i> , 2022, 63, 17-48.	0.3	3
115	ProthrombinxÂ@â€<scp>VF</scp> in chronic liver disease: Friend or foe?. <i>EMA - Emergency Medicine Australasia</i> , 2023, 35, 89-96.	0.5	3
116	Clinical and imaging predictors of the natural course of bland portal vein thrombus in cirrhotic patients. <i>Abdominal Radiology</i> , 0, , .	1.0	0
117	Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. <i>Trauma Surgery and Acute Care Open</i> , 2022, 7, e000936.	0.8	3
118	Long-Term Improvement in Liver Function Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Buddâ€™Chiari Syndrome. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1474-1479.	0.4	4
119	Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. <i>World Journal of Gastroenterology</i> , 2022, 28, 4061-4074.	1.4	11
120	Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions. <i>JHEP Reports</i> , 2022, 4, 100558.	2.6	3
121	Splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2022, 218, 8-16.	0.8	11
122	Anticoagulants and Antiplatelet Agents in Cirrhosis. , 2022, , 23-48.		0
123	Use of Newer Anticoagulants in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2022, 21, 45-51.	0.4	1
124	4D Flow MRI in the portal venous system: imaging and analysis methods, and clinical applications. <i>Radiologia Medica</i> , 2022, 127, 1181-1198.	4.7	15
125	Cirrhotic coagulopathy: A rebalanced hemostasis. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 523-533.	0.6	1
127	Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis. <i>Liver International</i> , 2023, 43, 155-159.	1.9	12
129	Minimal Risk of Hepatocellular Carcinoma in Noncirrhotic Budd-Chiari Syndrome: A Three-Decade Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2689-2691.e1.	2.4	1
130	Invited Commentary: Minimally Invasive Endovascular Management of Portal Vein Thrombosis. <i>Radiographics</i> , 2022, 42, E169-E170.	1.4	1
131	Portal Interventions in the Setting of Venous Thrombosis or Occlusion. <i>Radiographics</i> , 2022, 42, 1690-1704.	1.4	5



#	ARTICLE	IF	CITATIONS
133	Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: A prospective analysis of 302 procedures. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2786-2796.	1.9	12
134	Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines. <i>Meditinskiy Sovet</i> , 2022, , 70-82.	0.1	2
135	Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	0
136	Special Settings: Acute Variceal Bleeding and Portal Vein Thrombosis in Cirrhosis. , 2022, , 507-514.		0
137	Staging of Portal Vein Thrombosis: Recurrent Thrombosis and Prognostic Factors for Recurrence in Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (PVT). , 2022, , 599-611.		0
138	Anticoagulation in Splanchnic Vein Thrombosis With and Without Underlying Liver Disease. , 2022, , 649-667.		0
139	Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6435.	1.0	7
140	Large Bore Portal Vein Thrombectomy: An Inari FlowTriever Case Series. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 136-141.	0.9	4
141	Efficacy and safety of thrombolytic therapy for portal venous system thrombosis: A systematic review and meta-analysis. <i>Journal of Internal Medicine</i> , 2023, 293, 212-227.	2.7	3
142	Evaluation of the Patient with Markedly Abnormal Liver Enzymes. <i>Clinics in Liver Disease</i> , 2023, 27, 1-16.	1.0	3
143	Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 146, .	1.6	38
144	Cirrhosis, a Global and Challenging Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 6512.	1.0	2
145	Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 52-71.	1.9	2
146	Congenital Portosystemic Shunts in Cirrhosis and Portal Vein Thrombosis: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
147	Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges. <i>Expert Review of Hematology</i> , 2022, 15, 1031-1044.	1.0	4
148	EUS-guided coil placement and cyanoacrylate glue injection for gastric variceal bleeding with obvious spontaneous portosystemic shunts. <i>Endoscopic Ultrasound</i> , 2023, 12, 84.	0.6	1
149	Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis. , 2022, 1, .		15
151	Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome. <i>Transplantation</i> , 2023, 107, 1330-1340.	0.5	7

#	ARTICLE	IF	CITATIONS
153	Thrombocytopenia and liver disease: pathophysiology and periprocedural management. Hematology American Society of Hematology Education Program, 2022, 2022, 296-302.	0.9	2
154	Transjugular Intrahepatic Portosystemic Shunt in Chronic Portal Vein Thrombosis—From Routine Recommendations to Demanding Scenarios. Diagnostics, 2022, 12, 3100.	1.3	0
155	Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs. Cancers, 2023, 15, 11.	1.7	2
156	Hermeneutic phenomenology of lived experience of family caregivers of critically-ill patients sustained by healthcare technologies in Benin City, Nigeria. MGM Journal of Medical Sciences, 2022, 9, 465.	0.1	1
157	IX. Treatments of Varices, Intervein and Portal Venous Thrombus. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 66-73.	0.0	0
158	Management of splanchnic vein thrombosis. JHEP Reports, 2023, 5, 100667.	2.6	14
159	Clinically relevant increases in the INR and MELD score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis. Research and Practice in Thrombosis and Haemostasis, 2023, , 100052.	1.0	2
160	Establishment and verification a nomogram for predicting portal vein thrombosis presence among admitted cirrhotic patients. Frontiers in Medicine, 0, 9, .	1.2	0
161	Liver intensive care for the general intensivist. Anaesthesia, 2023, 78, 884-901.	1.8	2
162	Early thrombolysis combined with anticoagulation and antibiotics for acute portal venous system thrombosis secondary to intra-abdominal infection. Archives of Medical Science, 2023, 19, 283-287.	0.4	1
163	Periprocedural management of hemostatic alterations in patients with cirrhosis and vascular liver disorders: a step forward of the American Association for the Study of Liver Diseases. Hepatobiliary Surgery and Nutrition, 2023, 12, 105-109.	0.7	0
164	Tailoring stepwise treatment for Budd-Chiari syndrome: insights from the Asian Pacific Association for the Study of the Liver (APASL) consensus guidance. Hepatobiliary Surgery and Nutrition, 2023, 12, 118-120.	0.7	1
165	Beyond the Guidelines: Anticoagulant Treatment of Patients with Recent Portal Vein Thrombosis in the Setting of Liver Cirrhosis. Medicina Interna (Bucharest, Romania: 1991), 2022, 19, 37-45.	0.1	0
166	Anticoagulation for the Treatment of Portal Vein Thrombosis in Cirrhosis: A Systematic Review and Meta-Analysis of Comparative Studies. Journal of Clinical and Experimental Hepatology, 2023, 13, 404-413.	0.4	2
167	Association of IL-4 with pachychoroid neovasculopathy. Scientific Reports, 2023, 13, .	1.6	2
168	Cirrhosis Management in the Intensive Care Unit. Seminars in Liver Disease, 2023, 43, 117-132.	1.8	2
169	Chronic Liver Diseases and COVID-19: Database of General Hospital. Russian Archives of Internal Medicine, 2023, 13, 57-64.	0.0	0
170	Bleeding and thrombosis in cirrhosis. , 2023, , 165-202.		0

#	ARTICLE	IF	CITATIONS
171	Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis. <i>Journal of Clinical Medicine</i> , 2023, 12, 934.	1.0	1
172	Etiology, Presenting Features, and Endoscopic Findings of Portal Vein Hypertension in Children. <i>Journal of Comprehensive Pediatrics</i> , 2023, 14, .	0.1	0
173	Medical malpractice claims in Hepatology: Rates, Reasons, and Results. <i>Hepatology Communications</i> , 2023, 7, .	2.0	0
174	Haemostasis in cirrhosis: Understanding destabilising factors during acute decompensation. <i>Journal of Hepatology</i> , 2023, 78, 1037-1047.	1.8	17
175	Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients. <i>Medicina (Lithuania)</i> , 2023, 59, 292.	0.8	2
176	Oral Anticoagulation in Patients with Chronic Liver Disease. <i>Medicina (Lithuania)</i> , 2023, 59, 346.	0.8	3
177	Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin. <i>Leukemia and Lymphoma</i> , 2023, 64, 904-906.	0.6	1
178	Anticoagulant therapy for splanchnic vein thrombosis: recent updates for patients with liver cirrhosis. <i>Expert Review of Hematology</i> , 2023, 16, 121-129.	1.0	3
179	The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review. <i>Hepatology</i> , 2024, 79, 460-481.	3.6	9
180	Risk of severe disease and mortality of COVID-19 in patients with Budd-Chiari syndrome: A population-based matched cohort study. <i>Liver International</i> , 2023, 43, 1141-1144.	1.9	1
181	Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 127-141.	0.8	1
182	Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care. <i>European Journal of Anaesthesiology</i> , 2023, 40, 226-304.	0.7	61
183	Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. <i>American Journal of Hematology</i> , 2023, 98, 794-800.	2.0	6
184	Approach to thromboelastography-based transfusion in cirrhosis: An alternative perspective on coagulation disorders. <i>World Journal of Gastroenterology</i> , 0, 29, 1460-1474.	1.4	1
185	Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
187	Portal Vein Thrombosis Extending to the Superior Mesenteric and Splenic Veins Secondary to a Hypercoagulable State Due to Prior Abdominal Surgery, Hormonal Replacement Therapy, and Flaxseed Consumption. <i>Cureus</i> , 2023, , .	0.2	0
188	Advance of New Oral Anticoagulants in the Treatment of Portal Vein Thrombosis in Cir-rhosis. <i>Advances in Clinical Medicine</i> , 2023, 13, 3788-3795.	0.0	0
189	The use of prothrombin complex concentrate in chronic liver disease: A review of the literature. <i>Transfusion Medicine</i> , 2023, 33, 205-212.	0.5	3

#	ARTICLE	IF	CITATIONS
190	Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?. Digestive Diseases and Sciences, 0, , .	1.1	1
191	Hepatic Venous Occlusion Type of Buddâ€Chiari Syndrome versus Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstructive Syndrome: A Multi-Center Retrospective Study. Journal of Personalized Medicine, 2023, 13, 603.	1.1	2
192	Assessing the risk of surgery in patients with cirrhosis. Hepatology Communications, 2023, 7, .	2.0	5
193	Primary Buddâ€Chiari Syndrome. New England Journal of Medicine, 2023, 388, 1307-1316.	13.9	15
195	Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications. World Journal of Gastroenterology, 0, 29, 2336-2348.	1.4	0
233	Artificial intelligence in cirrhosis complications and acute liver failure. , 2023, , 179-194.		0
255	Coagulation Disorders in Patients with Alcohol-Related Liver Cirrhosis. , 2023, , 837-856.		0
288	Case Report: First attempt by off-label use of tenecteplase to treat acute extensive portal venous system thrombosis. Frontiers in Cardiovascular Medicine, 0, 11, .	1.1	0
289	Portal Vein Thrombosis in Cirrhosis. , 2023, , 347-349.		0